Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2026)
Caribou Biosciences (CRBU) reported Depreciation & Amortization (CF) of $649000.0 for Q1 2026, down 44.29% year-over-year from $1.2 million in Q1 2025, and down 4.84% on a QoQ basis from $682000.0 in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $649000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 44.29% year-over-year to $649000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 28.59% YoY) and the FY2025 annual result came in at $3.6 million, down 7.18% from the prior year.
- Depreciation & Amortization (CF) declined to $649000.0 in Q1 2026 per CRBU's latest filing, from $682000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.6 million in Q3 2023 and bottomed at $308000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $682000.0 (2025), against an average of $786352.9.
- The widest annual swing landed in 2023, when Depreciation & Amortization (CF) surged 250.89%; it then plunged 46.39% in 2025.
- Tracing CRBU's Depreciation & Amortization (CF) over 5 years: stood at $506000.0 in 2022, then jumped by 46.25% to $740000.0 in 2023, then soared by 60.0% to $1.2 million in 2024, then sank by 42.4% to $682000.0 in 2025, then fell by 4.84% to $649000.0 in 2026.
- Per Business Quant, the three latest CRBU Depreciation & Amortization (CF) figures stand at $649000.0 (Q1 2026), $682000.0 (Q4 2025), and $631000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | 649,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 649,000.00 |
| Mar 31, 2026 | 649,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Sep 30, 2025 | 631,000.00 |
| Sep 30, 2025 | 631,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 856,000.00 |
| Jun 30, 2024 | 856,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Dec 31, 2023 | 740,000.00 |
| Dec 31, 2023 | 740,000.00 |
| Sep 30, 2023 | 1.58 Mn |
| Sep 30, 2023 | 1.58 Mn |
| Jun 30, 2023 | 617,000.00 |
| Jun 30, 2023 | 617,000.00 |
| Mar 31, 2023 | 589,000.00 |
| Mar 31, 2023 | 589,000.00 |
| Dec 31, 2022 | 506,000.00 |
| Dec 31, 2022 | 506,000.00 |
| Sep 30, 2022 | 450,000.00 |
| Sep 30, 2022 | 450,000.00 |
| Jun 30, 2022 | 358,000.00 |
| Jun 30, 2022 | 358,000.00 |
| Mar 31, 2022 | 308,000.00 |
| Mar 31, 2022 | 308,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Sep 30, 2021 | 260,000.00 |
| Sep 30, 2021 | 260,000.00 |
| Jun 30, 2021 | 230,000.00 |
| Jun 30, 2021 | 230,000.00 |
| Mar 31, 2021 | 221,000.00 |
| Mar 31, 2021 | 221,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Dec 31, 2020 | 220,000.00 |
| Sep 30, 2020 | 226,000.00 |
| Sep 30, 2020 | 226,000.00 |
| Jun 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 200,000.00 |